ARTICLE | Product Development

Poly-nating the HCV space

November 1, 2004 8:00 AM UTC

The gaggle of companies developing oral polymerase inhibitors to treat HCV just got a little bigger, as Roche has signed with Pharmasset Inc. to develop PSI 6130, an oral nucleoside polymerase inhibitor in late preclinical development.

According to Abel De La Rosa, senior vice president of business development and strategy at Pharmasset, the companies plan to accelerate the program by running the remaining preclinical work on the compound in parallel. ...